Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,236
datasets available to search
ShareScore release 0.9.0
Dataset results
2,236 results for “inhalation”
Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis
ClinicalTrials.gov study NCT04060979. IPD Sharing: NO. Countries: 1. Publications: 1.
Inhaled Heparin for Hospitalised COVID-19 Patients
ClinicalTrials.gov study NCT04635241. IPD Sharing: UNDECIDED. Countries: 3. Publications: 3.
Evaluation of in vitro rat and human airway epithelial models for acute inhalation toxicity testing
Open the record for dataset details and reuse information.
The impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review
Open the record for dataset details and reuse information.
Data from: Efficacy and safety of four weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
BACKGROUND: Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β2 agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. TRIAL DESIGN: A multicentre, randomised, double-blind, parallel-group, placebo-controlled study. METHODS: Participants were patients with moderate-to-severe COPD treated with placebo or FF/VI 400/25 μg OD for 4 weeks. Study objectives were to assess the safety and efficacy of FF/VI 400/25 μg OD administered for 4 weeks via a novel dry powder inhaler. Co-primary end points were change from baseline in weighted mean (wm) heart rate 0–4 h postdose at day 28 and the incidence of adverse events (AEs). Secondary end points included change from baseline in trough forced expiratory volume in one second (FEV1) (23–24 h postdose; day 29) and wm FEV1 (0–4 h postdose; day 28). Patients were randomised to receive FF/VI 400/25 μg or placebo in a 2:1 ratio; all patients and investigators were blinded to active or placebo treatment. RESULTS: 60 patients (mean age 64 years) were randomised (FF/VI: n=40; placebo: n=20), and all contributed data to the analysis. Mean screening post-bronchodilator FEV1 per cent predicted was comparable between groups (FF/VI: 58.5%; placebo: 60.1%). The wm heart rate 0–4 h postdose was similar between groups (difference: 0.6 beats per minute; 95% CI −3.9 to 5.1). More on-treatment AEs were reported in the FF/VI group (68%) compared with the placebo group (50%). The most common drug-related AEs in the FF/VI group were oral candidiasis (8%) and dysphonia (5%). There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters. The FF/VI group had statistically greater improvements compared with placebo in trough FEV1 (mean difference 183 ml) and 0–4 h postdose wm FEV1 (mean difference 236 ml). CONCLUSION: FF/VI has a good safety and tolerability profile and improves lung function compared with placebo in patients with COPD.
Data from: Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis
Objective: Limited data exist concerning the role of inhaled hypertonic saline (HS) in decreasing pulmonary exacerbations in cystic fibrosis (CF), especially as more advanced stages of CF lung disease were excluded in prior studies. Herein we retrospectively determined the efficacy of inhaled HS in reducing CF pulmonary exacerbations when stratified according to the severity of CF lung disease. Stratification was based on the framework of the Pulmonary Therapeutics Committee's published gradation of obstructive lung physiology in CF, i.e., mild (FEV1 > 70%), moderate (FEV1 40-70%) and severe (FEV1 < 40%) lung disease, respectively. Design: A retrospective review of the Port CF® database over a 3-year period performed at an academic CF care center. Results: 340 pulmonary exacerbations were identified; inhaled HS was being used in 99 of these cases. Univariate analysis demonstrated a significant reduction in pulmonary exacerbations only in mild obstruction (OR=0.09, CI 0.01-0.81, p=0.012); however, multivariate logistic regression that adjusted for confounding variables showed a reduction in pulmonary exacerbations across the entire spectrum of obstructive lung disease when using inhaled HS i.e., mild obstructive CF lung disease (OR=0.17, CI 0.05-0.58, p=0.004), moderate obstructive CF lung disease (OR=0.39, CI 0.16-0.93, p=0.034), as well as severe obstructive CF lung disease (OR=0.02, CI 0.001-0.45, p=0.015). Moreover, inhaled HS appeared reasonably well tolerated across all stages of lung disease severity, and was discontinued in only 7% of cases (n=4) with severe lung disease. Conclusion: In this study, inhaled HS appeared to reduce pulmonary exacerbations in CF lung disease at all stages of obstruction. This underscores the importance of therapeutic inhaled HS in CF lung disease, regardless of severity of lung obstruction.
The impact of sleep hygiene education and lavender essential oil inhalation on the sleep quality and overall well-being of athletes who undergo late-evening training: a randomized controlled trial
Open the record for dataset details and reuse information.
Effects of inhaled double-branch dilator Umeclidinium/Vilanterol on pulmonary function and inflammatory factors in patients with stable chronic obstructive pulmonary disease
Open the record for dataset details and reuse information.
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT01040689. IPD Sharing: Not stated. Countries: 4. Publications: 0.
The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
ClinicalTrials.gov study NCT02636868. IPD Sharing: Not stated. Countries: 8. Publications: 0.
The Effect of Lavender Inhalation on Anxiety, Sleep, and Blood Pressure
ClinicalTrials.gov study NCT07192783. IPD Sharing: NO. Countries: 1. Publications: 0.
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
ClinicalTrials.gov study NCT01218009. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO)
ClinicalTrials.gov study NCT03376932. IPD Sharing: YES. Countries: 0. Publications: 1.
Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers
ClinicalTrials.gov study NCT03748758. IPD Sharing: NO. Countries: 1. Publications: 0.
Assessing and Improving Misuse of Inhalers in COPD Outpatients
ClinicalTrials.gov study NCT07264140. IPD Sharing: NO. Countries: 1. Publications: 0.
Using Tests in Preschool Children With Wheeze to Determine the Need for Inhaled Corticosteroid Therapy.
ClinicalTrials.gov study NCT04942483. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
ClinicalTrials.gov study NCT01305252. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
ClinicalTrials.gov study NCT02566044. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
ClinicalTrials.gov study NCT03367312. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
ClinicalTrials.gov study NCT03473236. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.